Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparing control and IL17A treated A2780-derived ovarian cancer stem cell

ABSTRACT: A2780-derived ovarian cancer stem cells were in vitro cultured in the presence of 10 ng/mL basic fibroblast growth factor , 20 ng/mL epidermal growth factor , 5 μg/mL insulin, 0.4% bovine serum albumin. Then ovarian cancer stem cells were stimulated for 4 and 6 hours in the presence or absence of 250ng/ml IL17A. Total RNA was isolated and processed according to the Agilentmanufacturer’s standard protocols

ORGANISM(S): Homo sapiens

PROVIDER: GSE39698 | GEO | 2012/07/28

SECONDARY ACCESSION(S): PRJNA171499

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Comparing control and IL17A treated A2780-derived ovarian cancer stem cell

Project description:A2780-derived ovarian cancer stem cells were in vitro cultured in the presence of 10 ng/mL basic fibroblast growth factor , 20 ng/mL epidermal growth factor , 5 M-NM-<g/mL insulin, 0.4% bovine serum albumin. Then ovarian cancer stem cells were stimulated for 4 and 6 hours in the presence or absence of 250ng/ml IL17A. Total RNA was isolated and processed according to the AgilentmanufacturerM-bM-^@M-^Ys standard protocols Gene expression in ovarian cancer stem cells from A2780 cell line was measured at IL17A stmulated (4 and 6 hours) and un-stmulated.

2012-07-27 | E-GEOD-39698 | biostudies-arrayexpress

RNA seq analysis of A2780 and A2780-ADR

Project description:We compared the global RNA expression level between doxorubicin-sensitive human ovarian cancer cell line A2780 and the adriamycin-resistant cell line A2780-ADR to elucidate the drug resistant related molecular mechanisms or targets.

2022-12-09 | GSE177038 | GEO

A2780 and OVCAR-3 Cells:Control vs. LS-98 treated

2011-06-01 | GSE29668 | GEO

Expression data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines.

2009-04-17 | E-GEOD-15372 | biostudies-arrayexpress

A2780 and OVCAR-3 Cells:Control vs. LS-98 treated

Project description:Transcriptional profiling of human ovarian cancer cells comparing control vehicle-treated A2780 and OVCAR-3 (Human ovarian cancer cell lines) cells with A2780 and OVCAR-3 cells treated with 5μM LS-98 for 24 hours.Goal was to determine the effects of LS-98 compound on the global A2780 and OVCAR-3 cells gene expression. One-condition experiment, control vehicle-treated A2780 and OVCAR-3 vs. LS098 treated-A2780 and OVCAR-3 cells. Biological replicates: 2 replicates.

2011-06-01 | E-GEOD-29668 | biostudies-arrayexpress

Differences in gene expression in A2780C20 vs. A2780

Project description:Differences in gene expression in A2780C20 vs. A2780 and A2780 treated with temsirolimus at 24-hr and 48-hr. The A2780 are human ovarian carcinoma cellls were purchased to the European Collection of Cell Cultures (ECACC). The A2780CP20 are cisplatin resisatnt cells derived of the A2780 cells. A2780CP20 cells were generated by Dr. Robert Ozols (J. Natl. Cancer Inst. 84, 264-267 (1992) by treatment of A2780 cells with incresing concentrations of cisplatin. The goal of this study is to determine whether the cisplatin and temsirolimus resistance are co-regulated. The objectives of this study are to identify additional genes differentially expressed in cisplatin sensitive and cisplatin resistant ovarain cancer cells and the changes in gene expreession upon temsirolimus treatment of A2780 cells.

2013-10-25 | GSE51683 | GEO

GDF15 is a secretary protein from ovarian cancer cell A2780 and induced by cisplatin in vivo

Project description:A2780 is a cisplatin sensitive ovarian cancer cell line. A2780 ovarian cancer cells was treated with different doses of cisplatin in an attempt to identify biomarkers that can be used to predict chemoresponse. We used microarrays to identify genes induced by cisplatin in a time dependent manner.

2018-11-08 | GSE122287 | GEO

Differences in gene expression in A2780C20 vs. A2780

2013-10-25 | E-GEOD-51683 | biostudies-arrayexpress

Transcription profiling by array of human A2780 ovarianc cancer cells and cisplatin resistant derivate cells treated with cisplatin or liposomal cisplatin

Project description:A2780 ovarian cancer cells and a cisplatin resistant derivate of A2780 cells, obtained from ECACC, UK, No. 93112519 [A2780] and No. 93112517 [A2780 cis] were seeded out in T-75 flasks at a density of 2x106 for A2780sens and 3x106 for A2780cis cells in 15 ml of medium and preincubated overnight. Medium was removed and 15 ml fresh medium (37M-0C) with different concentrations of cisplatin, liposomal cisplatin or empty liposomes were added and incubated for 72 h at 37M-0C in a 5% CO2 incubator. In case of A2780sens cells, 1.72 M-5M cisplatin (IC50 concentration) and in case of A2780cis cells 8.94 M-5M cisplatin (IC50 concentration) were added. Liposomal formulations contained equal cisplatin concentrations. Empty liposomes were added in the same concentration as the liposomal cisplatin, to analyze the impact of liposomal lipids (A2780sens: 0.80M-5mol lipid, A2780cis: 4.15 M-5mol lipid). After incubation, medium was removed and cells were washed thrice with 10 ml PBS. 1 ml RLT-buffer was added and cells lysates were stored at -80M-0C until RNA extraction.

2010-12-13 | E-MEXP-2840 | biostudies-arrayexpress

Promoter CpG island methylation data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines.

Project description:Cisplatin and carboplatin are the primary first-line therapies for the treatment of ovarian cancer. However, resistance to these platinum-based drugs occurs in the large majority of initially responsive tumors, subsequently resulting in a poor long-term prognosis. To model the onset of drug resistance, and investigate the DNA methylation alterations associated with cisplatin resistance, we treated clonally derived, drug-sensitive A2780 epithelial ovarian cancer cells with increasing concentrations of cisplatin. After several cycles of drug selection, the isogenic drug-sensitive and -resistant pairs were subjected to global CGI methylation microarray analyses. We treated clonally derived, drug-sensitive A2780 epithelial ovarian cancer cells with increasing concentrations of cisplatin. After several cycles of drug selection, the isogenic drug-sensitive and -resistant pairs were subjected to global CGI methylation analyses by differential methylation hybridization (DMH) using a customed 44K promoter CGI microarray.

2010-06-19 | E-GEOD-15373 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data